Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23157467,time to peak plasma concentration,"With twice-daily dosing of dalfampridine-ER, time to peak plasma concentration (3.2-3.9 hours) and apparent terminal plasma half-life (5.6-6.4 hours) are approximately twice those of immediate-release formulations, with comparable overall exposure and peak plasma concentrations (21.6 ng/mL) that were maintained at levels approximately 50% lower than immediate release.",Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23157467/),h,3.2-3.9,2343,DB06637,Dalfampridine
,23157467,apparent terminal plasma half-life,"With twice-daily dosing of dalfampridine-ER, time to peak plasma concentration (3.2-3.9 hours) and apparent terminal plasma half-life (5.6-6.4 hours) are approximately twice those of immediate-release formulations, with comparable overall exposure and peak plasma concentrations (21.6 ng/mL) that were maintained at levels approximately 50% lower than immediate release.",Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23157467/),h,5.6-6.4,2344,DB06637,Dalfampridine
,23157467,peak plasma concentrations,"With twice-daily dosing of dalfampridine-ER, time to peak plasma concentration (3.2-3.9 hours) and apparent terminal plasma half-life (5.6-6.4 hours) are approximately twice those of immediate-release formulations, with comparable overall exposure and peak plasma concentrations (21.6 ng/mL) that were maintained at levels approximately 50% lower than immediate release.",Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23157467/),[ng] / [ml],21.6,2345,DB06637,Dalfampridine
,23157467,Trough plasma concentrations,Trough plasma concentrations of 13-15 ng/mL are required to maintain efficacy.,Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23157467/),[ng] / [ml],13-15,2346,DB06637,Dalfampridine
,19966074,AUC(0-infinity) ratios,"AUC(0-infinity) ratios ranged from 175.3% to 398.7%, respectively, for mild and severe renal impairment.",Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19966074/),%,175.3,4488,DB06637,Dalfampridine
,19966074,AUC(0-infinity) ratios,"AUC(0-infinity) ratios ranged from 175.3% to 398.7%, respectively, for mild and severe renal impairment.",Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19966074/),%,398.7,4489,DB06637,Dalfampridine
,19966074,terminal disposition half-life,"Mean terminal disposition half-life was 6.4 hours in healthy individuals, compared with 7.4, 8.1, and 14.3 hours in patients with mild, moderate, and severe renal impairment, respectively.",Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19966074/),h,6.4,4490,DB06637,Dalfampridine
,19966074,terminal disposition half-life,"Mean terminal disposition half-life was 6.4 hours in healthy individuals, compared with 7.4, 8.1, and 14.3 hours in patients with mild, moderate, and severe renal impairment, respectively.",Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19966074/),h,7.4,4491,DB06637,Dalfampridine
,19966074,terminal disposition half-life,"Mean terminal disposition half-life was 6.4 hours in healthy individuals, compared with 7.4, 8.1, and 14.3 hours in patients with mild, moderate, and severe renal impairment, respectively.",Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19966074/),h,8.1,4492,DB06637,Dalfampridine
,19966074,terminal disposition half-life,"Mean terminal disposition half-life was 6.4 hours in healthy individuals, compared with 7.4, 8.1, and 14.3 hours in patients with mild, moderate, and severe renal impairment, respectively.",Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19966074/),h,14.3,4493,DB06637,Dalfampridine
,8792860,alpha-half-life,"Selected mean pharmacokinetic parameter estimates were alpha-half-life, 0.37 min; beta-half-life (biological half-life) for terminal slope, 109 min; and volume of distribution at steady state, 1036.18 mL/kg.",A method for determining 4-aminopyridine in plasma: pharmacokinetics in anaesthetized guinea pigs after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792860/),min,0.37,8247,DB06637,Dalfampridine
,8792860,beta-half-life (biological half-life) for terminal slope,"Selected mean pharmacokinetic parameter estimates were alpha-half-life, 0.37 min; beta-half-life (biological half-life) for terminal slope, 109 min; and volume of distribution at steady state, 1036.18 mL/kg.",A method for determining 4-aminopyridine in plasma: pharmacokinetics in anaesthetized guinea pigs after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792860/),min,109,8248,DB06637,Dalfampridine
,8792860,volume of distribution at steady state,"Selected mean pharmacokinetic parameter estimates were alpha-half-life, 0.37 min; beta-half-life (biological half-life) for terminal slope, 109 min; and volume of distribution at steady state, 1036.18 mL/kg.",A method for determining 4-aminopyridine in plasma: pharmacokinetics in anaesthetized guinea pigs after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792860/),[ml] / [kg],1036.18,8249,DB06637,Dalfampridine
,12723458,tmax,The drug was rapidly absorbed with a tmax approximately 1 hour for both groups; tmax was independent of dose.,Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723458/),h,1,18099,DB06637,Dalfampridine
,12723458,t 1/2,"Cmax and AUC0-infinity were linearly related to dose, and t 1/2 was 3 to 4 hours for both groups.",Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723458/),h,3 to 4,18100,DB06637,Dalfampridine
,6524755,Distribution half-life,"Distribution half-life was 12.08 minutes; elimination half-life, 128.96 minutes; volume of the central compartment, 1.48 L/kg; volume of distribution based on total area, 3.07 L/kg; volume of distribution at steady state, 2.75 L/kg; and body clearance, 16.57 ml/min/kg.",Pharmacokinetics of 4-aminopyridine in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524755/),min,12.08,26798,DB06637,Dalfampridine
,6524755,elimination half-life,"Distribution half-life was 12.08 minutes; elimination half-life, 128.96 minutes; volume of the central compartment, 1.48 L/kg; volume of distribution based on total area, 3.07 L/kg; volume of distribution at steady state, 2.75 L/kg; and body clearance, 16.57 ml/min/kg.",Pharmacokinetics of 4-aminopyridine in cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524755/),min,128.96,26799,DB06637,Dalfampridine
,6524755,volume of the central compartment,"Distribution half-life was 12.08 minutes; elimination half-life, 128.96 minutes; volume of the central compartment, 1.48 L/kg; volume of distribution based on total area, 3.07 L/kg; volume of distribution at steady state, 2.75 L/kg; and body clearance, 16.57 ml/min/kg.",Pharmacokinetics of 4-aminopyridine in cattle. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524755/),[l] / [kg],1.48,26800,DB06637,Dalfampridine
,6524755,volume of distribution based on total area,"Distribution half-life was 12.08 minutes; elimination half-life, 128.96 minutes; volume of the central compartment, 1.48 L/kg; volume of distribution based on total area, 3.07 L/kg; volume of distribution at steady state, 2.75 L/kg; and body clearance, 16.57 ml/min/kg.",Pharmacokinetics of 4-aminopyridine in cattle. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524755/),[l] / [kg],3.07,26801,DB06637,Dalfampridine
,6524755,volume of distribution at steady state,"Distribution half-life was 12.08 minutes; elimination half-life, 128.96 minutes; volume of the central compartment, 1.48 L/kg; volume of distribution based on total area, 3.07 L/kg; volume of distribution at steady state, 2.75 L/kg; and body clearance, 16.57 ml/min/kg.",Pharmacokinetics of 4-aminopyridine in cattle. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524755/),[l] / [kg],2.75,26802,DB06637,Dalfampridine
,6524755,body clearance,"Distribution half-life was 12.08 minutes; elimination half-life, 128.96 minutes; volume of the central compartment, 1.48 L/kg; volume of distribution based on total area, 3.07 L/kg; volume of distribution at steady state, 2.75 L/kg; and body clearance, 16.57 ml/min/kg.",Pharmacokinetics of 4-aminopyridine in cattle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6524755/),[ml] / [kg·min],16.57,26803,DB06637,Dalfampridine
,9292275,half-lives of elimination,"Peak plasma levels were found to occur between 16 and 17 min, and the half-lives of elimination were 65 and 71 min for IN and UN animals respectively.",Pharmacokinetics and pharmacodynamics of 4-aminopyridine in awake guinea pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9292275/),min,65,33303,DB06637,Dalfampridine
,9292275,half-lives of elimination,"Peak plasma levels were found to occur between 16 and 17 min, and the half-lives of elimination were 65 and 71 min for IN and UN animals respectively.",Pharmacokinetics and pharmacodynamics of 4-aminopyridine in awake guinea pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9292275/),min,71,33304,DB06637,Dalfampridine
,9292275,half-lives of elimination,The duration of action was approximately 1-1.5 half-lives of elimination beyond peak plasma levels.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in awake guinea pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9292275/),,1-1.5,33305,DB06637,Dalfampridine
,10761168,Cmax,The overall group mean Cmax of 27.7 +/- 6.2 ng/mL occurred at a tmax of 3.4 +/- 1.4 hours.,Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761168/),[ng] / [ml],27.7,44515,DB06637,Dalfampridine
,10761168,tmax,The overall group mean Cmax of 27.7 +/- 6.2 ng/mL occurred at a tmax of 3.4 +/- 1.4 hours.,Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761168/),h,3.4,44516,DB06637,Dalfampridine
,10761168,AUC0-12,AUC0-12 was 210.5 +/- 49.5 ng/mL.h.,Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761168/),[ng] / [h·ml],210.5,44517,DB06637,Dalfampridine
,10761168,AUCtmax,"For paraplegics, AUCtmax was 76.02 +/- 33.28 and for tetraplegics was significantly less at 51.25 +/- 20.36 (p = 0.037).",Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761168/),,76.02,44518,DB06637,Dalfampridine
,10761168,AUCtmax,"For paraplegics, AUCtmax was 76.02 +/- 33.28 and for tetraplegics was significantly less at 51.25 +/- 20.36 (p = 0.037).",Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761168/),,51.25,44519,DB06637,Dalfampridine
,23157466,oral clearance,The population median estimated oral clearance was 36 L/h for a 50-year-old woman with a creatinine clearance of 105 mL/min and 42 L/h for a comparable man.,Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23157466/),[l] / [h],36,68584,DB06637,Dalfampridine
,23157466,oral clearance,The population median estimated oral clearance was 36 L/h for a 50-year-old woman with a creatinine clearance of 105 mL/min and 42 L/h for a comparable man.,Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23157466/),l,42,68585,DB06637,Dalfampridine
,23157466,volume of distribution,The typical volume of distribution was 304 L for women and 403 L for men.,Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23157466/),l,304,68586,DB06637,Dalfampridine
,23157466,volume of distribution,The typical volume of distribution was 304 L for women and 403 L for men.,Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23157466/),l,403,68587,DB06637,Dalfampridine
,23157466,absorption rate constant,The estimated absorption rate constant was 1.22 hours(-1) in the fasted state and 2.22 hours(-1) when given with food.,Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23157466/),1/[hours],1.22,68588,DB06637,Dalfampridine
,23157466,absorption rate constant,The estimated absorption rate constant was 1.22 hours(-1) in the fasted state and 2.22 hours(-1) when given with food.,Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23157466/),1/[hours],2.22,68589,DB06637,Dalfampridine
,30756475,tmax,Pharmacokinetics demonstrated that testing coincided with the average tmax at 2.08 hours (SD 45 minutes).,"Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30756475/),h,2.08,74384,DB06637,Dalfampridine
,6842398,volume of the central compartment,The volume of the central compartment was 412 +/- 352 ml/kg (mean +/- S.D.) and the volume of distribution at steady state was 2517 +/- 363 ml/kg.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg],412,92560,DB06637,Dalfampridine
,6842398,volume of distribution at steady state,The volume of the central compartment was 412 +/- 352 ml/kg (mean +/- S.D.) and the volume of distribution at steady state was 2517 +/- 363 ml/kg.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg],2517,92561,DB06637,Dalfampridine
,6842398,Initial half-lives,Initial half-lives were 1.1 +/- 0.7 and 25.4 +/- 11 min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,1.1,92562,DB06637,Dalfampridine
,6842398,Initial half-lives,Initial half-lives were 1.1 +/- 0.7 and 25.4 +/- 11 min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,25.4,92563,DB06637,Dalfampridine
,6842398,terminal elimination half-life,The terminal elimination half-life was 125 +/- 23 min and total clearance was 21 +/- 4 ml/kg/min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,125,92564,DB06637,Dalfampridine
,6842398,total clearance,The terminal elimination half-life was 125 +/- 23 min and total clearance was 21 +/- 4 ml/kg/min.,Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),[ml] / [kg·min],21,92565,DB06637,Dalfampridine
,6842398,onset time,"The pharmacodynamic results included an onset time of 14 +/- 8 min, peak effect (maximum percentage of antagonism of twitch tension depression) 97 +/- 27% and duration of action 219 +/- 54 min.",Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,14,92566,DB06637,Dalfampridine
,6842398,duration of action,"The pharmacodynamic results included an onset time of 14 +/- 8 min, peak effect (maximum percentage of antagonism of twitch tension depression) 97 +/- 27% and duration of action 219 +/- 54 min.",Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842398/),min,219,92567,DB06637,Dalfampridine
,9862762,ED50,The total brain concentration (25 microM) of drug at the ED50 value (approximately 3 mg/kg) for protection against MES seizures was consistent with the reported affinity of AR-R 15896AR at the N-methyl-D- aspartic acid binding site (IC50 value = 1.3 microM).,"[S]-AR-R 15896AR-A novel anticonvulsant: acute safety, pharmacokinetic and pharmacodynamic properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862762/),[mg] / [kg],3,104817,DB06637,Dalfampridine
,9862762,IC50,The total brain concentration (25 microM) of drug at the ED50 value (approximately 3 mg/kg) for protection against MES seizures was consistent with the reported affinity of AR-R 15896AR at the N-methyl-D- aspartic acid binding site (IC50 value = 1.3 microM).,"[S]-AR-R 15896AR-A novel anticonvulsant: acute safety, pharmacokinetic and pharmacodynamic properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862762/),μM,1.3,104818,DB06637,Dalfampridine
,26849839,recovery,"Quantitative determination of fampridine (FAM), teriflunomide (TFM) and dimethyl fumarate (DMF) was performed in human plasma with the recovery values in the range of 85-115%.","Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849839/),%,85-115,116139,DB06637,Dalfampridine
,26849839,flow rate,The method utilizes an XBridge C18 silica column and a gradient elution with mobile phase consisting of ammonium formate and acetonitrile at a flow rate of 0.5 mL min(-1) .,"Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849839/),[ml] / [min],0.5,116140,DB06637,Dalfampridine
,26849839,detection,"With LC-MS, the detection and quantification limits for all of the analytes were 1 and 5 ng, respectively.","Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849839/),ng,1,116141,DB06637,Dalfampridine
,26849839,q,"With LC-MS, the detection and quantification limits for all of the analytes were 1 and 5 ng, respectively.","Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849839/),ng,1,116142,DB06637,Dalfampridine
,26849839,q,"With LC-MS, the detection and quantification limits for all of the analytes were 1 and 5 ng, respectively.","Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849839/),ng,5,116143,DB06637,Dalfampridine
,30465516,maximum plasma concentrations (Cmax),"The result revealed that the pharmacokinetic performance of QS11 achieved maximum plasma concentrations (Cmax) of 0.315 ± 0.011 µg/mL at Tmax of 2.0 ± 0.13 h, area under the curve (AUC0-∞) value 4.591 ± 0.163 µg/ml x h, elimination half-life (T1/2) 6.28 ± 0.71 h and elimination rate constant was found 0.110 ± 0.013 h-1 .","Design, Synthesis, Anticonvulsant Activity, Preclinical Study and Pharmacokinetic Performance of N-{[3-(4-chlorophenyl)-4-oxo-3, 4-dihydroquinazolin- 2-yl] methyl}, 2-[(2-isopropyl-5-methyl) 1-cyclo Hexylidene] Hydrazinecarboxamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465516/),[μg] / [ml],0.315,129030,DB06637,Dalfampridine
,30465516,Tmax,"The result revealed that the pharmacokinetic performance of QS11 achieved maximum plasma concentrations (Cmax) of 0.315 ± 0.011 µg/mL at Tmax of 2.0 ± 0.13 h, area under the curve (AUC0-∞) value 4.591 ± 0.163 µg/ml x h, elimination half-life (T1/2) 6.28 ± 0.71 h and elimination rate constant was found 0.110 ± 0.013 h-1 .","Design, Synthesis, Anticonvulsant Activity, Preclinical Study and Pharmacokinetic Performance of N-{[3-(4-chlorophenyl)-4-oxo-3, 4-dihydroquinazolin- 2-yl] methyl}, 2-[(2-isopropyl-5-methyl) 1-cyclo Hexylidene] Hydrazinecarboxamide. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465516/),h,2.0,129031,DB06637,Dalfampridine
,30465516,area under the curve (AUC0-∞),"The result revealed that the pharmacokinetic performance of QS11 achieved maximum plasma concentrations (Cmax) of 0.315 ± 0.011 µg/mL at Tmax of 2.0 ± 0.13 h, area under the curve (AUC0-∞) value 4.591 ± 0.163 µg/ml x h, elimination half-life (T1/2) 6.28 ± 0.71 h and elimination rate constant was found 0.110 ± 0.013 h-1 .","Design, Synthesis, Anticonvulsant Activity, Preclinical Study and Pharmacokinetic Performance of N-{[3-(4-chlorophenyl)-4-oxo-3, 4-dihydroquinazolin- 2-yl] methyl}, 2-[(2-isopropyl-5-methyl) 1-cyclo Hexylidene] Hydrazinecarboxamide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465516/),[μg] / [h·ml],4.591,129032,DB06637,Dalfampridine
,30465516,elimination half-life (T1/2),"The result revealed that the pharmacokinetic performance of QS11 achieved maximum plasma concentrations (Cmax) of 0.315 ± 0.011 µg/mL at Tmax of 2.0 ± 0.13 h, area under the curve (AUC0-∞) value 4.591 ± 0.163 µg/ml x h, elimination half-life (T1/2) 6.28 ± 0.71 h and elimination rate constant was found 0.110 ± 0.013 h-1 .","Design, Synthesis, Anticonvulsant Activity, Preclinical Study and Pharmacokinetic Performance of N-{[3-(4-chlorophenyl)-4-oxo-3, 4-dihydroquinazolin- 2-yl] methyl}, 2-[(2-isopropyl-5-methyl) 1-cyclo Hexylidene] Hydrazinecarboxamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465516/),h,6.28,129033,DB06637,Dalfampridine
,30465516,elimination rate constant,"The result revealed that the pharmacokinetic performance of QS11 achieved maximum plasma concentrations (Cmax) of 0.315 ± 0.011 µg/mL at Tmax of 2.0 ± 0.13 h, area under the curve (AUC0-∞) value 4.591 ± 0.163 µg/ml x h, elimination half-life (T1/2) 6.28 ± 0.71 h and elimination rate constant was found 0.110 ± 0.013 h-1 .","Design, Synthesis, Anticonvulsant Activity, Preclinical Study and Pharmacokinetic Performance of N-{[3-(4-chlorophenyl)-4-oxo-3, 4-dihydroquinazolin- 2-yl] methyl}, 2-[(2-isopropyl-5-methyl) 1-cyclo Hexylidene] Hydrazinecarboxamide. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465516/),1/[h],0.110,129034,DB06637,Dalfampridine
,12897638,plasma half-life,"Fampridine-SR was absorbed slowly (peak plasma concentration shortly after dosing, 2.6-3.7 hours) and eliminated (plasma half-life, 5.6-7.6 hours), and reached steady state after 4 days of twice-daily administration.",Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12897638/),h,5.6-7.6,149572,DB06637,Dalfampridine
,24150835,Steady-state AUC0-12,"Steady-state AUC0-12 among healthy subjects, 167.0 ± 55.3 ng h/mL, increased 74% and 151% with mild and moderate renal impairment, respectively.",Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24150835/),[h·ng] / [ml],167.0,173098,DB06637,Dalfampridine
,8208399,peak serum concentration,"Because 4-aminopyridine (AP) improves residual deficits in some multiple sclerosis (MS) patients but has a narrow toxic-to-therapeutic margin, we compared the safety and efficacy of two target peak serum concentration ranges (low: 30 to 59 ng/ml and high: 60 to 100 ng/ml).","The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8208399/),[ng] / [ml],30 to 59,174116,DB06637,Dalfampridine
,8208399,peak serum concentration,"Because 4-aminopyridine (AP) improves residual deficits in some multiple sclerosis (MS) patients but has a narrow toxic-to-therapeutic margin, we compared the safety and efficacy of two target peak serum concentration ranges (low: 30 to 59 ng/ml and high: 60 to 100 ng/ml).","The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8208399/),[ng] / [ml],60 to 100,174117,DB06637,Dalfampridine
above,8208399,peak levels,"AP treatment produced improvements in residual deficits in MS patients, but the occurrence of significant toxicity suggests that AP serum levels should be monitored and peak levels above 100 ng/ml should be avoided.","The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8208399/),[ng] / [ml],100,174118,DB06637,Dalfampridine
,24049893,Distribution half-life,"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),min,7.4,176035,DB06637,Dalfampridine
,24049893,elimination half-life,"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),min,259,176036,DB06637,Dalfampridine
,24049893,volume of the central compartment,"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),[l] / [kg],0.89,176037,DB06637,Dalfampridine
,24049893,volume of distribution (area),"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),[l] / [kg],1.98,176038,DB06637,Dalfampridine
,24049893,volume of distribution at steady state,"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),[l] / [kg],1.9,176039,DB06637,Dalfampridine
,24049893,total clearance,"Distribution half-life was 7.4 minutes, elimination half-life was 259 minutes, volume of the central compartment was 0.89 L/kg, volume of distribution (area) was 1.98 L/kg, volume of distribution at steady state was 1.9 L/kg, and total clearance was 5.3 ml min(-1) kg(-1).",Pharmacokinetics of 4-aminopyridine in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),[ml] / [kg·min],5.3,176040,DB06637,Dalfampridine
,24049893,elimination halflife,The 259-minute elimination halflife observed in the present study is consistent with prolonged clinical effectiveness observed in a previous study of antagonism of xylazine/ketamine anesthesia by 4-AP in horses.,Pharmacokinetics of 4-aminopyridine in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24049893/),min,259,176041,DB06637,Dalfampridine
,14970964,tmax,Fampridine-SR had a mean tmax of 2.2 to 3.0 hours and a mean t(1/2) of 5.7 to 6.9 hours.,"Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14970964/),h,2.2 to 3.0,183121,DB06637,Dalfampridine
,14970964,t(1/2),Fampridine-SR had a mean tmax of 2.2 to 3.0 hours and a mean t(1/2) of 5.7 to 6.9 hours.,"Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14970964/),h,5.7 to 6.9,183122,DB06637,Dalfampridine
,14970964,Vd/F,"Mean Vd/F (415.4-528.0 L) and Cl/F (51.4-57.7 L/h) were independent of dosage, as were mean tmax and t(1/2) across dosages.","Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14970964/),l,415.4-528.0,183123,DB06637,Dalfampridine
,14970964,Cl/F,"Mean Vd/F (415.4-528.0 L) and Cl/F (51.4-57.7 L/h) were independent of dosage, as were mean tmax and t(1/2) across dosages.","Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14970964/),[l] / [h],51.4-57.7,183124,DB06637,Dalfampridine
,26686828,relative recoveries,The method was validated over a concentration range of 0.1-100ng/mL for all the three analytes with relative recoveries ranging from 69 to 82%.,"A high throughput flow gradient LC-MS/MS method for simultaneous determination of fingolimod, fampridine and prednisone in rat plasma, application to in vivo perfusion study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26686828/),%,69 to 82,183278,DB06637,Dalfampridine
,19922891,T(max),T(max) occurred at 3.36 to 3.92 hours after dosing; the apparent elimination t((1/2)) was 5.47 hours.,"Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922891/),h,3.36 to 3.92,184490,DB06637,Dalfampridine
,19922891,apparent elimination t((1/2)),T(max) occurred at 3.36 to 3.92 hours after dosing; the apparent elimination t((1/2)) was 5.47 hours.,"Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922891/),h,5.47,184491,DB06637,Dalfampridine
,19922892,T(max),"The T(max) did not differ significantly between day 1, day 8, day 15, and the single-dose study (range, 3.25-3.78 hours).","Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922892/),h,3.25-3.78,186047,DB06637,Dalfampridine
,19922892,C(max),"C(max) values on days 8 and 15 (66.7 and 62.6 ng/mL, respectively) were significantly higher than those on day 1 (48.6 ng/mL) and in the single-dose study (50.5 ng/mL) (all, P < 0.001), reflecting accumulation of fampridine with multiple dosing.","Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922892/),[ng] / [ml],66.7,186048,DB06637,Dalfampridine
,19922892,C(max),"C(max) values on days 8 and 15 (66.7 and 62.6 ng/mL, respectively) were significantly higher than those on day 1 (48.6 ng/mL) and in the single-dose study (50.5 ng/mL) (all, P < 0.001), reflecting accumulation of fampridine with multiple dosing.","Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922892/),[ng] / [ml],62.6,186049,DB06637,Dalfampridine
,19922892,C(max),"C(max) values on days 8 and 15 (66.7 and 62.6 ng/mL, respectively) were significantly higher than those on day 1 (48.6 ng/mL) and in the single-dose study (50.5 ng/mL) (all, P < 0.001), reflecting accumulation of fampridine with multiple dosing.","Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922892/),[ng] / [ml],48.6,186050,DB06637,Dalfampridine
,19922892,C(max),"C(max) values on days 8 and 15 (66.7 and 62.6 ng/mL, respectively) were significantly higher than those on day 1 (48.6 ng/mL) and in the single-dose study (50.5 ng/mL) (all, P < 0.001), reflecting accumulation of fampridine with multiple dosing.","Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922892/),[ng] / [ml],50.5,186051,DB06637,Dalfampridine
,19922892,C(max)/C(min),"Values for C(max)/C(min) did not differ significantly between day 1 and the single-dose study (2.44 and 2.43, respectively) or between days 8 and 15 (2.90 and 2.88, respectively); however, the single-dose and day-1 values differed significantly from the day-8 and day-15 values (P < or = 0.001).","Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922892/),,2.44,186052,DB06637,Dalfampridine
,19922892,C(max)/C(min),"Values for C(max)/C(min) did not differ significantly between day 1 and the single-dose study (2.44 and 2.43, respectively) or between days 8 and 15 (2.90 and 2.88, respectively); however, the single-dose and day-1 values differed significantly from the day-8 and day-15 values (P < or = 0.001).","Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922892/),,2.43,186053,DB06637,Dalfampridine
,19922892,C(max)/C(min),"Values for C(max)/C(min) did not differ significantly between day 1 and the single-dose study (2.44 and 2.43, respectively) or between days 8 and 15 (2.90 and 2.88, respectively); however, the single-dose and day-1 values differed significantly from the day-8 and day-15 values (P < or = 0.001).","Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922892/),,2.90,186054,DB06637,Dalfampridine
,19922892,C(max)/C(min),"Values for C(max)/C(min) did not differ significantly between day 1 and the single-dose study (2.44 and 2.43, respectively) or between days 8 and 15 (2.90 and 2.88, respectively); however, the single-dose and day-1 values differed significantly from the day-8 and day-15 values (P < or = 0.001).","Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922892/),,2.88,186055,DB06637,Dalfampridine
,3240914,half-lives,"Plasma concentrations decreased biexponentially with half-lives of 9.0 +/- 5.7 min and 140 +/- 36 min, respectively.","Pharmacokinetics and pharmacodynamics of 2,4-diaminopyridine in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240914/),min,9.0,186419,DB06637,Dalfampridine
,3240914,half-lives,"Plasma concentrations decreased biexponentially with half-lives of 9.0 +/- 5.7 min and 140 +/- 36 min, respectively.","Pharmacokinetics and pharmacodynamics of 2,4-diaminopyridine in the cat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240914/),min,140,186420,DB06637,Dalfampridine
,3240914,volume of the central compartment,"The volume of the central compartment was 0.85 +/- 0.27 L/kg, and the volume of distribution in the steady state was 3.1 +/- 1.1 L/kg.","Pharmacokinetics and pharmacodynamics of 2,4-diaminopyridine in the cat. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240914/),[l] / [kg],0.85,186421,DB06637,Dalfampridine
,3240914,volume of distribution in the steady state,"The volume of the central compartment was 0.85 +/- 0.27 L/kg, and the volume of distribution in the steady state was 3.1 +/- 1.1 L/kg.","Pharmacokinetics and pharmacodynamics of 2,4-diaminopyridine in the cat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240914/),[l] / [kg],3.1,186422,DB06637,Dalfampridine
,3240914,Total plasma clearance,Total plasma clearance was 18 +/- 5 ml/kg/min.,"Pharmacokinetics and pharmacodynamics of 2,4-diaminopyridine in the cat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240914/),[ml] / [kg·min],18,186423,DB06637,Dalfampridine
,26152130,maximum serum concentrations (Cmax),"After administration of 10 or 20 mg 3,4-DAP following food intake, the maximum serum concentrations (Cmax) were 8.09 ± 4.47 ng/mL and 35.8 ± 15.7 ng/mL, respectively (mean ± standard deviation; SD), and the areas under the serum concentration-time curve (extrapolated to infinity) were 639 ± 213 ng x min/mL and 2,097 ± 936 ng x min/mL (mean ± SD), respectively.","Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26152130/),[ng] / [ml],8.09,201370,DB06637,Dalfampridine
,26152130,maximum serum concentrations (Cmax),"After administration of 10 or 20 mg 3,4-DAP following food intake, the maximum serum concentrations (Cmax) were 8.09 ± 4.47 ng/mL and 35.8 ± 15.7 ng/mL, respectively (mean ± standard deviation; SD), and the areas under the serum concentration-time curve (extrapolated to infinity) were 639 ± 213 ng x min/mL and 2,097 ± 936 ng x min/mL (mean ± SD), respectively.","Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26152130/),[ng] / [ml],35.8,201371,DB06637,Dalfampridine
,26152130,areas under the serum concentration-time curve,"After administration of 10 or 20 mg 3,4-DAP following food intake, the maximum serum concentrations (Cmax) were 8.09 ± 4.47 ng/mL and 35.8 ± 15.7 ng/mL, respectively (mean ± standard deviation; SD), and the areas under the serum concentration-time curve (extrapolated to infinity) were 639 ± 213 ng x min/mL and 2,097 ± 936 ng x min/mL (mean ± SD), respectively.","Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26152130/),[min·ng] / [ml],639,201372,DB06637,Dalfampridine
,26152130,areas under the serum concentration-time curve,"After administration of 10 or 20 mg 3,4-DAP following food intake, the maximum serum concentrations (Cmax) were 8.09 ± 4.47 ng/mL and 35.8 ± 15.7 ng/mL, respectively (mean ± standard deviation; SD), and the areas under the serum concentration-time curve (extrapolated to infinity) were 639 ± 213 ng x min/mL and 2,097 ± 936 ng x min/mL (mean ± SD), respectively.","Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26152130/),[min·ng] / [ml],"2,097",201373,DB06637,Dalfampridine
,31419315,half-life,"After intravenous administration of 3,4-DAP to rats, the half-life of 3,4-DAP was 15.9 ± 3.9 min and the volume of distribution at steady-state was 2.8 ± 0.7 L/kg.","Pharmacokinetics and tissue distribution of 3,4-diaminopyridine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31419315/),min,15.9,220382,DB06637,Dalfampridine
,31419315,volume of distribution at steady-state,"After intravenous administration of 3,4-DAP to rats, the half-life of 3,4-DAP was 15.9 ± 3.9 min and the volume of distribution at steady-state was 2.8 ± 0.7 L/kg.","Pharmacokinetics and tissue distribution of 3,4-diaminopyridine in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31419315/),[l] / [kg],2.8,220383,DB06637,Dalfampridine
,19302905,Peak plasma radioactivity,"Peak plasma radioactivity was reached at 1 hour after dosing, with a median concentration of 72.9 ng x mL(-1).",Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302905/),[ng] / [ml],72.9,224771,DB06637,Dalfampridine
,19302905,concentration,"Peak plasma radioactivity was reached at 1 hour after dosing, with a median concentration of 72.9 ng x mL(-1).",Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302905/),[ng] / [ml],72.9,224772,DB06637,Dalfampridine
,19302905,t(1/2),"There was complete disappearance of radioactivity by 24 hours (limit of quantitation, 400 disintegrations/min per peak), and the calculated median t(1/2) was 3.14 hours.",Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302905/),h,3.14,224773,DB06637,Dalfampridine
,19302905,Total cumulative recovery,"Total cumulative recovery of (14)C-radioactivity was 96.36%, with only 0.51% of drug recovered in feces.",Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302905/),%,96.36,224774,DB06637,Dalfampridine
,19302905,Total cumulative recovery,"Total cumulative recovery of (14)C-radioactivity was 96.36%, with only 0.51% of drug recovered in feces.",Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302905/),%,0.51,224775,DB06637,Dalfampridine
